{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042414","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.721970+00:00","generated_at":"2026-06-11T13:29:39.821995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron Therapeutics Q2 2023 revenue up; secures $80M in new financing; cost cuts expected to save $75M through 2025","bullets":["Oncology care franchise net product sales $27.3M (Q2 2023) vs $25.1M (Q2 2022); acute care franchise sales $4.5M vs $2.5M.","Full-year 2023 oncology care net product sales guidance reiterated at $99M-$103M.","Closed $29.7M equity placement in July 2023; entered $50M working capital facility in August 2023 with $24.5M drawn.","Cost reduction program expected to save ~$75M in cash spend through 2025; new management team in place.","Favorable Markman hearing outcome in CINVANTI patent litigation against Fresenius Kabi."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042414","json":"https://secwatch.observer/filing/0000950170-23-042414.json","markdown":"https://secwatch.observer/filing/0000950170-23-042414.md","text":"https://secwatch.observer/filing/0000950170-23-042414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/0000950170-23-042414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/hrtx-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:29:39.821995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0701219ed67931ab49ca53eaaa6ca3b748afc13b","claim":"HERON THERAPEUTICS, INC. /DE/ updated its the three and six months ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On August 14, 2023, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023042414/0000950170-23-042414-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}